Eintrag weiter verarbeiten
Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure
Gespeichert in:
| Zeitschriftentitel: | American Journal of Physiology-Renal Physiology |
|---|---|
| Personen und Körperschaften: | , , , , , , |
| In: | American Journal of Physiology-Renal Physiology, 290, 2006, 2, S. F273-F278 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
American Physiological Society
|
| Schlagwörter: |
| author_facet |
Costello-Boerrigter, Lisa C. Smith, William B. Boerrigter, Guido Ouyang, John Zimmer, Christopher A. Orlandi, Cesare Burnett, John C. Costello-Boerrigter, Lisa C. Smith, William B. Boerrigter, Guido Ouyang, John Zimmer, Christopher A. Orlandi, Cesare Burnett, John C. |
|---|---|
| author |
Costello-Boerrigter, Lisa C. Smith, William B. Boerrigter, Guido Ouyang, John Zimmer, Christopher A. Orlandi, Cesare Burnett, John C. |
| spellingShingle |
Costello-Boerrigter, Lisa C. Smith, William B. Boerrigter, Guido Ouyang, John Zimmer, Christopher A. Orlandi, Cesare Burnett, John C. American Journal of Physiology-Renal Physiology Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure Physiology |
| author_sort |
costello-boerrigter, lisa c. |
| spelling |
Costello-Boerrigter, Lisa C. Smith, William B. Boerrigter, Guido Ouyang, John Zimmer, Christopher A. Orlandi, Cesare Burnett, John C. 1931-857X 1522-1466 American Physiological Society Physiology http://dx.doi.org/10.1152/ajprenal.00195.2005 <jats:p> Diuretics are frequently required to treat fluid retention in patients with congestive heart failure (CHF). Unfortunately, they can lead to a decline in renal function, electrolyte depletion, and neurohumoral activation. Arginine vasopressin (AVP) promotes renal water reabsorption via the V<jats:sub>2</jats:sub> receptor, and its levels are increased in CHF. This study was designed to assess the effects of a single oral dose of tolvaptan, a selective V<jats:sub>2</jats:sub>-receptor blocker, in the absence of other medications, on renal function in human CHF and to compare this to the effects of a single oral dose of furosemide. We hypothesized that V<jats:sub>2</jats:sub>-receptor antagonism would yield a diuresis comparable to furosemide but would not adversely affect renal hemodynamics, plasma electrolyte concentration, or neurohumoral activation in stable human CHF. Renal and neurohumoral effects of tolvaptan and furosemide were assessed in an open-label, randomized, placebo-controlled crossover study in 14 patients with NYHA II-III CHF. Patients received placebo or 30 mg of tolvaptan on day 1 and were crossed over to the other medication on day 3. On day 5, all subjects received 80 mg of furosemide. Tolvaptan and furosemide induced similar diuretic responses. Unlike tolvaptan, furosemide increased urinary sodium and potassium excretion and decreased renal blood flow. Tolvaptan, furosemide, and placebo did not differ with respect to mean arterial pressure, glomerular filtration rate, or serum sodium and potassium. We conclude that tolvaptan is an effective aquaretic with no adverse effects on renal hemodynamics or serum electrolytes in patients with mild to moderate heart failure. </jats:p> Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure American Journal of Physiology-Renal Physiology |
| doi_str_mv |
10.1152/ajprenal.00195.2005 |
| facet_avail |
Online Free |
| finc_class_facet |
Biologie |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE1Mi9hanByZW5hbC4wMDE5NS4yMDA1 |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE1Mi9hanByZW5hbC4wMDE5NS4yMDA1 |
| institution |
DE-D275 DE-Bn3 DE-Brt1 DE-Zwi2 DE-D161 DE-Gla1 DE-Zi4 DE-15 DE-Pl11 DE-Rs1 DE-105 DE-14 DE-Ch1 DE-L229 |
| imprint |
American Physiological Society, 2006 |
| imprint_str_mv |
American Physiological Society, 2006 |
| issn |
1931-857X 1522-1466 |
| issn_str_mv |
1931-857X 1522-1466 |
| language |
English |
| mega_collection |
American Physiological Society (CrossRef) |
| match_str |
costelloboerrigter2006vasopressin2receptorantagonismaugmentswaterexcretionwithoutchangesinrenalhemodynamicsorsodiumandpotassiumexcretioninhumanheartfailure |
| publishDateSort |
2006 |
| publisher |
American Physiological Society |
| recordtype |
ai |
| record_format |
ai |
| series |
American Journal of Physiology-Renal Physiology |
| source_id |
49 |
| title |
Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure |
| title_unstemmed |
Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure |
| title_full |
Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure |
| title_fullStr |
Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure |
| title_full_unstemmed |
Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure |
| title_short |
Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure |
| title_sort |
vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure |
| topic |
Physiology |
| url |
http://dx.doi.org/10.1152/ajprenal.00195.2005 |
| publishDate |
2006 |
| physical |
F273-F278 |
| description |
<jats:p> Diuretics are frequently required to treat fluid retention in patients with congestive heart failure (CHF). Unfortunately, they can lead to a decline in renal function, electrolyte depletion, and neurohumoral activation. Arginine vasopressin (AVP) promotes renal water reabsorption via the V<jats:sub>2</jats:sub> receptor, and its levels are increased in CHF. This study was designed to assess the effects of a single oral dose of tolvaptan, a selective V<jats:sub>2</jats:sub>-receptor blocker, in the absence of other medications, on renal function in human CHF and to compare this to the effects of a single oral dose of furosemide. We hypothesized that V<jats:sub>2</jats:sub>-receptor antagonism would yield a diuresis comparable to furosemide but would not adversely affect renal hemodynamics, plasma electrolyte concentration, or neurohumoral activation in stable human CHF. Renal and neurohumoral effects of tolvaptan and furosemide were assessed in an open-label, randomized, placebo-controlled crossover study in 14 patients with NYHA II-III CHF. Patients received placebo or 30 mg of tolvaptan on day 1 and were crossed over to the other medication on day 3. On day 5, all subjects received 80 mg of furosemide. Tolvaptan and furosemide induced similar diuretic responses. Unlike tolvaptan, furosemide increased urinary sodium and potassium excretion and decreased renal blood flow. Tolvaptan, furosemide, and placebo did not differ with respect to mean arterial pressure, glomerular filtration rate, or serum sodium and potassium. We conclude that tolvaptan is an effective aquaretic with no adverse effects on renal hemodynamics or serum electrolytes in patients with mild to moderate heart failure. </jats:p> |
| container_issue |
2 |
| container_start_page |
0 |
| container_title |
American Journal of Physiology-Renal Physiology |
| container_volume |
290 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792341992611512338 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T16:28:43.214Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Vasopressin-2-receptor+antagonism+augments+water+excretion+without+changes+in+renal+hemodynamics+or+sodium+and+potassium+excretion+in+human+heart+failure&rft.date=2006-02-01&genre=article&issn=1522-1466&volume=290&issue=2&pages=F273-F278&jtitle=American+Journal+of+Physiology-Renal+Physiology&atitle=Vasopressin-2-receptor+antagonism+augments+water+excretion+without+changes+in+renal+hemodynamics+or+sodium+and+potassium+excretion+in+human+heart+failure&aulast=Burnett&aufirst=John+C.&rft_id=info%3Adoi%2F10.1152%2Fajprenal.00195.2005&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792341992611512338 |
| author | Costello-Boerrigter, Lisa C., Smith, William B., Boerrigter, Guido, Ouyang, John, Zimmer, Christopher A., Orlandi, Cesare, Burnett, John C. |
| author_facet | Costello-Boerrigter, Lisa C., Smith, William B., Boerrigter, Guido, Ouyang, John, Zimmer, Christopher A., Orlandi, Cesare, Burnett, John C., Costello-Boerrigter, Lisa C., Smith, William B., Boerrigter, Guido, Ouyang, John, Zimmer, Christopher A., Orlandi, Cesare, Burnett, John C. |
| author_sort | costello-boerrigter, lisa c. |
| container_issue | 2 |
| container_start_page | 0 |
| container_title | American Journal of Physiology-Renal Physiology |
| container_volume | 290 |
| description | <jats:p> Diuretics are frequently required to treat fluid retention in patients with congestive heart failure (CHF). Unfortunately, they can lead to a decline in renal function, electrolyte depletion, and neurohumoral activation. Arginine vasopressin (AVP) promotes renal water reabsorption via the V<jats:sub>2</jats:sub> receptor, and its levels are increased in CHF. This study was designed to assess the effects of a single oral dose of tolvaptan, a selective V<jats:sub>2</jats:sub>-receptor blocker, in the absence of other medications, on renal function in human CHF and to compare this to the effects of a single oral dose of furosemide. We hypothesized that V<jats:sub>2</jats:sub>-receptor antagonism would yield a diuresis comparable to furosemide but would not adversely affect renal hemodynamics, plasma electrolyte concentration, or neurohumoral activation in stable human CHF. Renal and neurohumoral effects of tolvaptan and furosemide were assessed in an open-label, randomized, placebo-controlled crossover study in 14 patients with NYHA II-III CHF. Patients received placebo or 30 mg of tolvaptan on day 1 and were crossed over to the other medication on day 3. On day 5, all subjects received 80 mg of furosemide. Tolvaptan and furosemide induced similar diuretic responses. Unlike tolvaptan, furosemide increased urinary sodium and potassium excretion and decreased renal blood flow. Tolvaptan, furosemide, and placebo did not differ with respect to mean arterial pressure, glomerular filtration rate, or serum sodium and potassium. We conclude that tolvaptan is an effective aquaretic with no adverse effects on renal hemodynamics or serum electrolytes in patients with mild to moderate heart failure. </jats:p> |
| doi_str_mv | 10.1152/ajprenal.00195.2005 |
| facet_avail | Online, Free |
| finc_class_facet | Biologie |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE1Mi9hanByZW5hbC4wMDE5NS4yMDA1 |
| imprint | American Physiological Society, 2006 |
| imprint_str_mv | American Physiological Society, 2006 |
| institution | DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161, DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1, DE-L229 |
| issn | 1931-857X, 1522-1466 |
| issn_str_mv | 1931-857X, 1522-1466 |
| language | English |
| last_indexed | 2024-03-01T16:28:43.214Z |
| match_str | costelloboerrigter2006vasopressin2receptorantagonismaugmentswaterexcretionwithoutchangesinrenalhemodynamicsorsodiumandpotassiumexcretioninhumanheartfailure |
| mega_collection | American Physiological Society (CrossRef) |
| physical | F273-F278 |
| publishDate | 2006 |
| publishDateSort | 2006 |
| publisher | American Physiological Society |
| record_format | ai |
| recordtype | ai |
| series | American Journal of Physiology-Renal Physiology |
| source_id | 49 |
| spelling | Costello-Boerrigter, Lisa C. Smith, William B. Boerrigter, Guido Ouyang, John Zimmer, Christopher A. Orlandi, Cesare Burnett, John C. 1931-857X 1522-1466 American Physiological Society Physiology http://dx.doi.org/10.1152/ajprenal.00195.2005 <jats:p> Diuretics are frequently required to treat fluid retention in patients with congestive heart failure (CHF). Unfortunately, they can lead to a decline in renal function, electrolyte depletion, and neurohumoral activation. Arginine vasopressin (AVP) promotes renal water reabsorption via the V<jats:sub>2</jats:sub> receptor, and its levels are increased in CHF. This study was designed to assess the effects of a single oral dose of tolvaptan, a selective V<jats:sub>2</jats:sub>-receptor blocker, in the absence of other medications, on renal function in human CHF and to compare this to the effects of a single oral dose of furosemide. We hypothesized that V<jats:sub>2</jats:sub>-receptor antagonism would yield a diuresis comparable to furosemide but would not adversely affect renal hemodynamics, plasma electrolyte concentration, or neurohumoral activation in stable human CHF. Renal and neurohumoral effects of tolvaptan and furosemide were assessed in an open-label, randomized, placebo-controlled crossover study in 14 patients with NYHA II-III CHF. Patients received placebo or 30 mg of tolvaptan on day 1 and were crossed over to the other medication on day 3. On day 5, all subjects received 80 mg of furosemide. Tolvaptan and furosemide induced similar diuretic responses. Unlike tolvaptan, furosemide increased urinary sodium and potassium excretion and decreased renal blood flow. Tolvaptan, furosemide, and placebo did not differ with respect to mean arterial pressure, glomerular filtration rate, or serum sodium and potassium. We conclude that tolvaptan is an effective aquaretic with no adverse effects on renal hemodynamics or serum electrolytes in patients with mild to moderate heart failure. </jats:p> Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure American Journal of Physiology-Renal Physiology |
| spellingShingle | Costello-Boerrigter, Lisa C., Smith, William B., Boerrigter, Guido, Ouyang, John, Zimmer, Christopher A., Orlandi, Cesare, Burnett, John C., American Journal of Physiology-Renal Physiology, Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure, Physiology |
| title | Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure |
| title_full | Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure |
| title_fullStr | Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure |
| title_full_unstemmed | Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure |
| title_short | Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure |
| title_sort | vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure |
| title_unstemmed | Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure |
| topic | Physiology |
| url | http://dx.doi.org/10.1152/ajprenal.00195.2005 |